Volume 26, Issue 4 (Iranian South Medical Journal 2024)
Iran South Med J 2024, 26(4): 224-235 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Firuzyar T, Ghaedian T, Amirzadegani S. The Correlation of Serum Adiponectin Level with Evidence of Coronary Artery Disease in SPECT Myocardial Perfusion Imaging. Iran South Med J 2024; 26 (4) :224-235
URL: http://ismj.bpums.ac.ir/article-1-1858-en.html
URL: http://ismj.bpums.ac.ir/article-1-1858-en.html
1- Department of Nuclear Medicine, Namazi Hospital, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2- Department of Nuclear Medicine, Namazi Hospital, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran , tghaedian@gmail.com
3- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
2- Department of Nuclear Medicine, Namazi Hospital, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran , tghaedian@gmail.com
3- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract: (197 Views)
Background: Adiponectin is one of the specific hormones of adipose tissue that plays an important role in insulin sensitivity, and low levels of adiponectin are associated with atherosclerosis and coronary artery diseases. Considering the controversial role of adiponectin in coronary artery diseases, the aim of this study is to investigate the relationship between adiponectin and evidence of coronary artery diseases in conventional single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI).
Materials and Methods: This prospective cross-sectional study was conducted on patients who were sus-pected of coronary artery disease who referred to a nuclear medicine department in a 6-month period for MPI. The correlation of serum adiponectin level was compared with these parameters as well as with fac-tors such as age, gender and coronary artery disease risk factors.
Results: In this study, 172 patients with suspected coronary disease referring for nuclear cardiac scan were included. The mean age of the patients was 57.83±10.64 years with a range of 28-87 years. The re-sults of our study showed that the serum levels of adiponectin were not significantly different between the patients with normal and abnormal nuclear scans, but the level of this hormone was significantly lower in women and in patients with diabetes. Also, none of the quantitative parameters of MPI had any signifi-cant relationships with serum adiponectin.
Conclusion: The present findings showed that there is no significant correlation between nuclear imaging parameters and serum levels of adiponectin, but the level of this hormone was significantly lower in the patients with diabetes and in women.
Materials and Methods: This prospective cross-sectional study was conducted on patients who were sus-pected of coronary artery disease who referred to a nuclear medicine department in a 6-month period for MPI. The correlation of serum adiponectin level was compared with these parameters as well as with fac-tors such as age, gender and coronary artery disease risk factors.
Results: In this study, 172 patients with suspected coronary disease referring for nuclear cardiac scan were included. The mean age of the patients was 57.83±10.64 years with a range of 28-87 years. The re-sults of our study showed that the serum levels of adiponectin were not significantly different between the patients with normal and abnormal nuclear scans, but the level of this hormone was significantly lower in women and in patients with diabetes. Also, none of the quantitative parameters of MPI had any signifi-cant relationships with serum adiponectin.
Conclusion: The present findings showed that there is no significant correlation between nuclear imaging parameters and serum levels of adiponectin, but the level of this hormone was significantly lower in the patients with diabetes and in women.
Keywords: Adiponectin, coronary artery disease, myocardial perfusion imaging, quantitative and semi-quantitative MPI parameters
Type of Study: Original |
Subject:
Cardiovascular System
Received: 2024/01/17 | Accepted: 2024/02/17 | Published: 2024/03/3
Received: 2024/01/17 | Accepted: 2024/02/17 | Published: 2024/03/3
References
1. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108(14): 1664-72. [DOI]
2. Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47(8 Suppl): C13-8. [DOI]
3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444(7121): 875-80. [DOI]
4. Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008; 117(5): 605-13. [DOI]
5. Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J 2007; 153(6): 907-17. [DOI]
6. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26(3): 439-51. [DOI]
7. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423(6941): 762-9. [DOI]
8. Yamauchi T, Iwabu M, Okada-Iwabu M, et al. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 15-23. [DOI]
9. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148(3): 293-300. [DOI]
10. Ricci R, Bevilacqua F. The potential role of leptin and adiponectin in obesity: a comparative review. Vet J 2012; 191(3): 292-8. [DOI]
11. Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med 2008; 14(11-12): 741-51. [DOI]
12. Shams M, Rasekhi Kazerouni A, Ostovan MA, et al. The relationship between serum adiponectin levels with the presence and severity of coronary artery disease. Arch Iran Med 2012; 15(10): 611-6. [PubMed]
13. Ghaedian T, Behbudnia T, Dehghani P. Comparison of Quantitative Perfusion and Function Parameters of Gated-SPECT Myocardial Perfusion Imaging in Patients With Concordant and Discordant Left Bundle-Branch Block. Clin Nucl Med 2020; 45(1): 7-10. [DOI]
14. Ghaedian T, Mirzaei M, Ghaedian MM. Relationship between Baseline ECG Abnormalities and Quantitative Perfusion Parameters of Myocardial Perfusion Findings. Iran South Med J 2020; 22(6): 381-91. [DOI]
15. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009; 73(4): 608-14. [DOI]
16. Smitka K, Maresova D. Adipose Tissue as an Endocrine Organ: An Update on Pro-inflammatory and Anti-inflammatory Microenvironment. Prague Med Rep 2015; 116(2): 87-111. [DOI]
17. Romacho T, Elsen M, Röhrborn D, et al. Adipose tissue and its role in organ crosstalk. Acta Physiol (Oxf) 2014; 210(4): 733-53. [DOI]
18. Knights AJ, Funnell AP, Pearson RC, et al. Adipokines and insulin action: A sensitive issue. Adipocyte 2014; 3(2): 88-96. [DOI]
19. Altinova AE, Toruner F, Bukan N, et al. Decreased plasma adiponectin is associated with insulin resistance and HDL cholesterol in overweight subjects. Endocr J 2007; 54(2): 221-6. [DOI]
20. Kręcki R, Krzemińska-Pakuła M, Drożdż J, et al. Relationship of serum angiogenin, adiponectin and resistin levels with biochemical risk factors and the angiographic severity of three-vessel coronary disease. Cardiol J 2010; 17(6): 599-606. [PubMed]
21. Kręcki R, Krzemińska-Pakuła M, Peruga JZ, et al. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up. Med Sci Monit 2011; 17(1): CR26-32. [DOI]
22. Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008; 57(4): 980-6. [DOI]
23. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361(9353): 226-8. [DOI]
24. Khorasani ZM, Choobkar S, Bagheri RK, et al. The Relationship Between Adiponectin Serum Level and Coronary Artery Disease in Type 2 Diabetic Patients. Acta Med Iran 2021; 59(3): 142-7. [DOI]
25. Nabipour I, Gorgin A, Motamedi N, et al. The Effects of Resveratrol Supplementation on the Level of Adiponectin and Leptin in Type 2 Diabetic Patients. Iran South Med J 2018; 21(4): 267-75. [Article]
26. Yang L, Li B, Zhao Y, et al. Prognostic value of adiponectin level in patients with coronary artery disease: a systematic review and metaanalysis. Lipids Health Dis 2019; 18(1): 227. [DOI]
27. Vidhate D, Thomas J, Gupte A. Association of circulating levels of Adiponectin and IL-6 with incidence and severity of the coronary artery disease in patients undergoing Coronary Artery Bypass Graft (CABG). International J Med Sci Curr Res 2021; 4(2): 215-220. [Article]
28. Farid W, Ibraheem R, Ahmed AA. The correlation between serum adiponectin levels and severity of coronary artery disease. Menoufia Med J 2019; 32(1): 181-186. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
